Mohammed Al-Adhami
About
Mohammed Al-Adhami is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Genetics.
According to data from OpenAlex, Mohammed Al-Adhami has authored 51 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Immunology, 18 papers in Pulmonary and Respiratory Medicine and 14 papers in Genetics. Recurrent topics in Mohammed Al-Adhami's work include Complement system in diseases (19 papers), Hemoglobinopathies and Related Disorders (9 papers) and Blood groups and transfusion (9 papers). Mohammed Al-Adhami is often cited by papers focused on Complement system in diseases (19 papers), Hemoglobinopathies and Related Disorders (9 papers) and Blood groups and transfusion (9 papers). Mohammed Al-Adhami collaborates with scholars based in United States, Hong Kong and China. Mohammed Al-Adhami's co-authors include Heather L. Davis, Arthur Μ. Krieg, Donald Woytowitz, Donald Gravenor, Gary Albert, Julie Lekstrom-Himes, Susan M. Efler, Christian Manegold, J. Mezger and David Readett and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Mohammed Al-Adhami
48 papers receiving 694 citations
Peers
Mohammed Al-Adhami
Federico Chiurazzi Italy
Peter J. Norsworthy United Kingdom
Matthew D. Cascino United States
Jack O. Egan United States
Nadège Pelletier France
Sean Agbor-Enoh United States
A Alfarano Italy
Masatoshi Deguchi Japan
Orrawadee Hanvivatvong Thailand
Lone Schejbel Denmark
Citations per year, relative to Mohammed Al-Adhami Mohammed Al-Adhami (= 1×)
peers
Federico Chiurazzi
Countries citing papers authored by Mohammed Al-Adhami
Since
Specialization
Citations
This map shows the geographic impact of Mohammed Al-Adhami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Al-Adhami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Al-Adhami more than expected).
Fields of papers citing papers by Mohammed Al-Adhami
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mohammed Al-Adhami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Al-Adhami. The network helps show where Mohammed Al-Adhami may publish in the future.
Co-authorship network of co-authors of Mohammed Al-Adhami
This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed Al-Adhami. A scholar is included among the top collaborators of Mohammed Al-Adhami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed Al-Adhami. Mohammed Al-Adhami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Patriquin, Christopher J., Andrija Bogdanović, Morag Griffin, et al.. (2024). Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Advances in Therapy. 41(5). 2050–2069.
2.
Yeh, Michael, et al.. (2024). Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan. Drugs in R&D. 24(2). 169–177.
3.
Panse, Jens, Nicolas Daguindau, Sonia Okuyama, et al.. (2024). Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors. PLoS ONE. 19(7). e0306407–e0306407.
4.
Wong, Raymond, Jesse Fishman, Koo Wilson, et al.. (2023). Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Advances in Therapy. 40(4). 1571–1589.
5.
Wong, Raymond, Yeow Tee Goh, David Gómez‐Almaguer, et al.. (2023). Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria. Blood Advances. 7(11). 2468–2478.
6.
Al‐Obaidi, Mazen M. Jamil, et al.. (2023). Antibiotic prescription in the management of endodontic infections amongst Iraqi final-year undergraduate dental students. Brazilian journal of oral sciences. 22. e230171–e230171.
7.
Castro, Carlos M. de, et al.. (2023). A Real-World Evidence Review of Post-Marketing Safety and Compliance with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US. Blood. 142(Supplement 1). 5647–5647.
8.
Latour, Régis Peffault de, Jeff Szer, Ilene C. Weitz, et al.. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet Haematology. 9(9). e648–e659.
9.
Cella, David, Sujata P. Sarda, Jesse Fishman, et al.. (2022). Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study. Annals of Hematology. 101(9). 1905–1914.
10.
Wong, Raymond, Humphrey Pullon, Andrija Bogdanović, et al.. (2022). Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Annals of Hematology. 101(9). 1971–1986.
11.
Risitano, Antonio M., et al.. (2022). P833: CATEGORIZING HEMATOLOGICAL RESPONSE TO PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A POST HOC ANALYSIS OF THE PHASE 3 PRINCE STUDY DATA. HemaSphere. 6. 727–728.
12.
Latour, Régis Peffault de, Cristina Castro, Jeff Szer, et al.. (2021). Long-term effects in subgroups of patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan versus eculizumab: 48-week analysis of pegasus phase 3 trial. HemaSphere. 702–702.
13.
Pierceall, William E., Kam Sprott, Tuomas Heikkinen, et al.. (2011). Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Human Pathology. 43(9). 1363–1375.
14.
Kelly, Karen, Jimmy J. Hwang, Geoffrey I. Shapiro, et al.. (2010). Phase I study of AV-412, a novel, irreversible EGFR inhibitor, administered intermittently in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3103–3103.
15.
Manegold, Christian, Donald Gravenor, Donald Woytowitz, et al.. (2008). Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(24). 3979–3986.
16.
Ghalib, R., E. Läwitz, B. Freilich, et al.. (2007). [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA. Journal of Hepatology. 46. S245–S246.
17.
McHutchison, John G., Bruce R. Bacon, Stuart C. Gordon, et al.. (2007). Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 46(5). 1341–1349.
18.
Manegold, C., et al.. (2005). Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC). mediaTUM (Technical University of Munich).
19.
Gravenor, Donald, Donald Woytowitz, J. Mezger, et al.. (2005). CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. Journal of Clinical Oncology. 23(16_suppl). 7039–7039.
20.
Boothe, D.M., Scott A. Brown, Gwendolyn D. Fate, et al.. (1996). Plasma disposition of clindamycin microbiological activity in cats after single oral doses of clindamycin hydrochloride as either capsules or aqueous solution. Journal of Veterinary Pharmacology and Therapeutics. 19(6). 491–494.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Federico Chiurazzi Breakdown of academic impact, for papers by Peter J. Norsworthy Breakdown of academic impact, for papers by Matthew D. Cascino Breakdown of academic impact, for papers by Jack O. Egan Breakdown of academic impact, for papers by Nadège Pelletier Breakdown of academic impact, for papers by Sean Agbor-Enoh Breakdown of academic impact, for papers by A Alfarano Breakdown of academic impact, for papers by Masatoshi Deguchi Breakdown of academic impact, for papers by Orrawadee Hanvivatvong Breakdown of academic impact, for papers by Lone Schejbel